LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

Home・Listă Acțiuni・Voyager Therapeutics Inc

Voyager Therapeutics Inc

Închisă

4.03 2.54

Cumpără Vinde

Rezumat

Modificarea prețului

24h

Curent

Minim

Maxim

4.07

Indicatori cheie
By Trading Economics
Venit	466K -27M
Vânzări	2M 15M
Marjă de profit	-178.834
Angajați	141
EBITDA	-2M -29M

Recomandări
By TipRanks
Recomandări	Puternic Cumpărare
Prognoză pe 12 luni	+273.83% upside

Dividende
By Dow Jones
Următoarele câștiguri	11 mai 2026

Statistici piață
By TradingEconomics
Capitalizare de piață	5.9M 234M
Deschiderea anterioară	1.49
Închiderea anterioară	4.03

Scor tehnic

By Trading Central

Încredere

Bearish Evidence

3.17 / 3.4644 Suport & Rezistență

Voyager Therapeutics Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

8 mai 2026, 23:55 UTC

Câștiguri

Review & Preview: Still Going Strong -- Barrons.com

8 mai 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

8 mai 2026, 20:49 UTC

Câștiguri

Why the Gap Between Chip and Software Stocks Keeps Getting Wider -- Barrons.com

8 mai 2026, 20:25 UTC

Câștiguri

These Stocks Are Today's Movers: Rocket Lab, Moderna, HubSpot, Nvidia, CoreWeave, Trade Desk, Cloudflare, Fluor, Akamai, IREN, and More -- Barrons.com

8 mai 2026, 19:43 UTC

Câștiguri

Cencosud 1Q Rev $4.565B >CENCOSUD.SN

8 mai 2026, 19:43 UTC

Câștiguri

Cencosud 1Q Net $115M

8 mai 2026, 19:20 UTC

Market Talk

Oil Futures End Session Higher, But Down on the Week -- Market Talk

8 mai 2026, 19:18 UTC

Câștiguri

Monster and Celsius Earnings Show Energy-Drink Fatigue Is Far From Over -- Barrons.com

8 mai 2026, 19:16 UTC

Câștiguri

This Mini Berkshire Hathaway Is a Buy. An Activist Investor Is Pushing to Break It Up. -- Barrons.com

8 mai 2026, 19:08 UTC

Câștiguri

This Mini Berkshire Hathaway Is a Buy. An Activist Investor Is Pushing to Break It Up. -- Barrons.com

8 mai 2026, 19:05 UTC

Câștiguri

Investors Feared Energy-Drink Fatigue. Monster and Celsius Earnings Offered Reassurance. -- Barrons.com

8 mai 2026, 19:02 UTC

Market Talk

U.S. Natural Gas Futures Little Changed on Week -- Market Talk

8 mai 2026, 18:51 UTC

Câștiguri

Memory Stocks Continue to Surge. What's Driving Micron and Sandisk Higher. -- Barrons.com

8 mai 2026, 18:49 UTC

Câștiguri

These Stocks Are Today's Movers: Rocket Lab, Moderna, HubSpot, Nvidia, CoreWeave, Trade Desk, Cloudflare, Fluor, Akamai, IREN, and More -- Barrons.com

8 mai 2026, 18:41 UTC

Câștiguri

McDonald's Stock Rises on Earnings Beat. The Value Push Needs to Maintain Momentum. -- Barrons.com

8 mai 2026, 17:38 UTC

Market Talk

U.S. Oil Rig Count Rises By 2 to 410 -- Market Talk

8 mai 2026, 17:14 UTC

Câștiguri

How High Gas Prices Need to Rise to Boost Electric Vehicle Sales -- Barrons.com

8 mai 2026, 17:04 UTC

Market Talk

Zcash Caps Off Parabolic Week -- Market Talk

8 mai 2026, 16:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

8 mai 2026, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

8 mai 2026, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

8 mai 2026, 15:39 UTC

Market Talk

Gold Seen Transitioning Away From 'Corrective Phase' -- Market Talk

8 mai 2026, 15:39 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

8 mai 2026, 15:39 UTC

Market Talk

Canada's Job Market Sees Worst Start in Years -- Market Talk

8 mai 2026, 15:36 UTC

Market Talk

A Jump in Canada's Jobless Rate May Turn Out to Be a Blip -- Market Talk

8 mai 2026, 15:20 UTC

Market Talk

'Altcoin Season' Indicator on the Rise -- Market Talk

8 mai 2026, 15:20 UTC

Market Talk

Câștiguri

Enbridge Gas Pipelines, Distribution Units Drive 1Q Beat -- Market Talk

8 mai 2026, 15:05 UTC

Market Talk

Bitcoin Slips Back Below the $80k Mark -- Market Talk

8 mai 2026, 14:42 UTC

Market Talk

Tough Times for Canadian Teenagers Looking for Work -- Market Talk

8 mai 2026, 14:39 UTC

Market Talk

Canadian Labor Market Suggests Persistent Higher Inflation Unlikely -- Market Talk

Comparație

Modificare preț

Voyager Therapeutics Inc Așteptări

Obiectiv de preț

By TipRanks

273.83% sus

Prognoză pe 12 luni

Medie 15.14 USD 273.83%

Maxim 25 USD

Minim 8 USD

În baza a 9 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruVoyager Therapeutics Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

9 ratings

Cumpărare

Păstrare

Vânzare

Ținând cont de 9 analiști care au acordat evaluări ale acțiunilor Voyager Therapeutics Inc - Dist în ultimele 3 luni.

Scor tehnic

By Trading Central

3.17 / 3.4644Suport & Rezistență

Recent bearish events outweigh bullish events.

All events are bearish.

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

Despre Voyager Therapeutics Inc

Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.